A Phase II, Randomized, Open-label Platform Study of Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
A phase 2, open-label, investigator sponsored study of selinexor (KPT-330) in patients with advanced thymic epithelial tumor (TET) progressing after primary chemotherapy (SELECT)
A Phase II single-arm trial to investigate tepotinib in stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure of at least one prior active therapy, including a platinum-doublet-containing regimen
Randomized, Open-Label Phase 3 Trial of Nivolumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
![Alert Sign](https://www.hackensackumc.org/wp-content/themes/hackensack-umc/images/exclamation-triangle.svg")
![Close Alert Box](https://www.hackensackumc.org/wp-content/themes/hackensack-umc/images/X.svg")
